Skip to content

GRAIL, Inc. GRAL Depreciation

Depreciation at other companies

Abbott logo
AbbottABT
Adaptive Biotechnologies logo
Adaptive BiotechnologiesADPT
Celcuity logo
CelcuityCELC
Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE
Tango Therapeutics logo
Tango TherapeuticsTNGX
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ

Other financials

Income statement

See full
Revenue$40.8M+28.1%
Operating income-$135.8M+11.6%
Net income-$93.2M+12.3%
EPS (diluted)-$2.29+26.1%

Balance sheet

See full
Cash & equivalents$76.3M-44.4%
Total debt$51.0M-20.7%
Total equity$2.5B+3.6%
Total assets$2.8B-1.5%

Cash flow

See full
Operating cash flow-$87.0M+8.4%
CapEx$503.0K+711%
Free cash flow-$87.5M+8.0%

Valuation

See full
Market cap$2.62B+145%
Enterprise value$2.6B+164%
P/S16.8×+8.6×

Profitability

See full
Operating margin-348.7%-153pp
Net margin-253.2%-115pp
FCF margin-187.2%-60.4pp

Returns & leverage

See full
Return on equity-16.1%
Debt / equity0.0×
Current ratio11.7×+2.0×

Where this comes from

Reported directly by GRAIL, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: GRAIL, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about GRAIL, Inc.'s depreciation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is GRAIL, Inc.'s depreciation?
GRAIL, Inc. (GRAL) reported depreciation of $4.21M in Q1 2026.
How has GRAIL, Inc.'s depreciation changed year-over-year?
GRAIL, Inc.'s depreciation decreased by 10.3% year-over-year, from $4.7M to $4.21M.
What is the long-term trend for GRAIL, Inc.'s depreciation?
Over 2 years (2022 to 2025), GRAIL, Inc.'s depreciation has grown at a 4.7% compound annual growth rate (CAGR), from $16.43M to $18.01M.